Home Palliative Care Where Palliative Care Is Provided

Where Palliative Care Is Provided

๐Ÿ“‹ Key Information Summary

๐Ÿ“‹
  • Palliative care can be delivered across multiple settings โ€” home, hospital, residential aged care, hospice/palliative care units, and via community outreach services โ€” and the optimal setting is guided by patient preference, symptom burden, carer capacity, and available resources.
  • Approximately 54% of Australians express a preference to die at home, yet only around 14โ€“16% achieve this; bridging this gap requires robust community palliative care services and advance care planning.
  • Home-based palliative care enables familiar surroundings and family involvement but depends on adequate carer support, 24-hour telephone advice, timely equipment delivery, and regular visiting by specialist or generalist palliative care teams.
  • Hospital-based palliative care is appropriate for acute symptom crises (uncontrolled pain, bleeding, respiratory distress), complex procedures requiring inpatient facilities, or when home/residential care is unsafe or unavailable.
  • Dedicated palliative care units (hospices) provide specialist interdisciplinary care for patients with complex refractory symptoms, offering higher nurse-to-patient ratios and expertise in end-of-life symptom management.
  • Hospital-in-the-home programs increasingly allow palliative interventions (subcutaneous infusions, IV antibiotics, blood transfusions) to be delivered in the community, reducing unnecessary hospital admissions.
  • Residential aged care facilities (RACFs) are the place of death for approximately 30% of Australians; integrating palliative care principles and specialist support into RACFs is a national priority.
  • Rural and remote Australians face significant barriers to palliative care access including workforce shortages, limited specialist services, vast travel distances, and reduced availability of after-hours support and equipment.
  • Telehealth has transformed rural palliative care delivery, enabling specialist consultations, family meetings, and symptom review to occur without the burden of long-distance travel.
  • Aboriginal and Torres Strait Islander communities have distinct cultural needs around death, dying, and Country; culturally safe palliative care must incorporate family-centred models, community-controlled health services, and the option to return to Country.
  • Advance care planning (ACP) is integral regardless of setting; the Australian Government's National Palliative Care Strategy (2018) mandates that ACP discussions are initiated early and documented accessibly.
  • The Palliative Care Outcomes Collaboration (PCOC) provides national benchmarking data on palliative care outcomes across Australian settings, enabling quality improvement.

Introduction & Australian Epidemiology

Palliative care is an approach that improves the quality of life of patients and their families facing life-limiting illness, through the prevention and relief of suffering by means of early identification, impeccable assessment, and treatment of pain and other physical, psychosocial, and spiritual problems (World Health Organization, 2020). In Australia, palliative care is recognised as a core component of the healthcare system, with the National Palliative Care Strategy 2018 establishing a framework for equitable access regardless of diagnosis, age, location, or cultural background.

The setting in which palliative care is delivered profoundly influences the patient and family experience, clinical outcomes, and healthcare costs. The choice of setting depends on a complex interplay of factors including patient and family preference, symptom complexity, carer availability and capability, proximity to services, cultural considerations, and the broader healthcare infrastructure available in a given region.

Australian Mortality and Palliative Care Use

Approximately 169,300 Australians died in 2022, with an estimated 60โ€“70% requiring some form of palliative care in the last 12 months of life. Data from the Australian Institute of Health and Welfare (AIHW) indicate the following distribution of place of death nationally:

Place of Death Approximate % Trend
Hospital (including emergency departments) ~50โ€“54% Gradually declining
Residential aged care facility ~28โ€“32% Stable
Home ~14โ€“16% Slowly increasing
Hospice / palliative care unit ~3โ€“5% Stable
Other (e.g. en route, community) ~1โ€“3% Variable

Despite strong community preference for home-based death, a significant mismatch persists between preference and reality. The 2023 Grattan Institute report noted that investing in community palliative care could reduce emergency department presentations in the last year of life by up to 35% and decrease hospital bed-days by approximately 25%, representing substantial cost savings to the health system.

National Policy Context

Key national policy instruments shaping palliative care settings include:

  • National Palliative Care Strategy 2018: Six pillars including access, quality, workforce, and data.
  • Palliative Care Australia (PCA): Peak body advocacy for universal access.
  • PCOC (Palliative Care Outcomes Collaboration): National benchmarking since 2006, now covering >95% of specialist palliative care services.
  • Aged Care Quality Standards (2019): Standard 3 requires palliative care planning in RACFs.
  • Medicare Benefits Schedule (MBS): Items for specialist palliative medicine (Items 98, 99 series) and GP chronic disease management plans (Items 721, 723).
  • Commonwealth Home Support Programme (CHSP) & Home Care Packages: Funding mechanisms for community-based palliative support.

๐Ÿ  Home Care

Home-based palliative care allows patients to remain in familiar surroundings, maintain independence, and be close to family, pets, and community. It is the preferred setting for many Australians and, when adequately supported, is associated with high patient and carer satisfaction, reduced hospital admissions, and lower healthcare costs.

Models of Home-Based Palliative Care

Model Description Typical Provider
Generalist palliative care at home GP-led, community nursing, allied health; suitable for patients with stable symptoms and good carer support General practitioners, district nursing services, CHSP providers
Specialist community palliative care Consultant-led multidisciplinary team; for complex symptoms, active dying, or specialist medication management State-funded specialist palliative care teams (e.g. Silver Chain in WA, Palliative Care Victoria community teams)
Hospital-in-the-home (HITH) Acute-level interventions delivered at home: subcutaneous infusions, IV antibiotics, transfusions, paracentesis Hospital-based HITH programs (e.g. Royal Melbourne Hospital HITH, Alfred Health)
Volunteer-based support Companionship, respite for carers, practical assistance; does not replace clinical care Palliative Care Volunteer programs, St Vincent de Paul, local hospice volunteers
Telehealth-supported home care Video consultations for symptom review, family meetings, and after-hours triage MBS telehealth items (e.g. Items 99200โ€“99215 for specialist telehealth)

Essential Requirements for Safe Home-Based Palliative Care

  • Carer capacity: At least one willing and able primary carer, with access to respite and carer education programs (Carer Gateway: 1800 422 737).
  • 24-hour telephone support: Access to a palliative care nurse or after-hours GP helpline for urgent symptom management advice (e.g. NURSE-ON-CALL 1300 60 60 24 in Victoria, Healthdirect 1800 022 222 nationally).
  • Equipment: Hospital-grade bed, pressure-relieving mattress, suction (if needed), syringe driver, oxygen concentrator โ€” typically funded through state palliative care programs or NDIS.
  • Medication access: Anticipatory medications stocked in the home (subcutaneous morphine, midazolam, hyoscine butylbromide, metoclopramide, haloperidol); emergency medication kits managed by community pharmacy or specialist palliative care team.
  • Regular visiting schedule: Minimum daily visits in the terminal phase; twice-weekly visits during stable phase, adjusted to need.
  • Emergency plan: Written action plan for acute deterioration, including whom to call, what medications to administer, and when to call an ambulance.
โš ๏ธ
Safety concern: Home-based palliative care should be reconsidered when: (1) symptoms are refractory and require continuous specialist monitoring; (2) the carer is experiencing burnout or is medically unwell; (3) the home environment is unsafe (hoarding, falls risk, no running water); or (4) there is active conflict in the household. Timely escalation to inpatient palliative care prevents crisis hospital admissions.

Medications Commonly Used in Home Palliative Care

๐Ÿ’Š
Morphine (Immediate-Release)
MS Continยฎ ยท Kapanolยฎ ยท Sevredolยฎ ยท Opioid analgesic
Adult dose (opioid-naive) 2.5โ€“5 mg PO every 4 hours PRN; or 1โ€“2.5 mg SC every 4 hours PRN
Paediatric dose 0.1โ€“0.2 mg/kg PO every 4 hours; SC 0.05โ€“0.1 mg/kg every 4 hours
Renal adjustment Reduce dose by 50% if eGFR 10โ€“50 mL/min; avoid if eGFR <10 โ€” use fentanyl or alfentanil
PBS status โœ” PBS General Benefit
๐Ÿ’Š
Midazolam
Hypnovelยฎ ยท Hypnotic / anxiolytic / anticonvulsant
Adult dose (terminal agitation) 2.5โ€“5 mg SC stat, then 10โ€“30 mg over 24 hours via SC infusion (syringe driver)
Paediatric dose 0.05โ€“0.1 mg/kg SC stat; 0.1โ€“0.4 mg/kg over 24 hours SC infusion
Renal adjustment Use lower end of dosing range; active metabolites may accumulate
PBS status โœ” PBS General Benefit
๐Ÿ’Š
Hyoscine Butylbromide
Buscopanยฎ ยท Anticholinergic / anti-secretory
Adult dose (death rattle) 20 mg SC stat, then 60โ€“80 mg over 24 hours via SC infusion
Paediatric dose 0.2โ€“0.4 mg/kg SC; max 10 mg SC stat <6 years
Renal adjustment No specific adjustment; use with caution
PBS status โœ” PBS General Benefit

Funding and Equipment Access

  • State palliative care programs: Most states and territories fund equipment loans (bed, mattress, commode, syringe drivers) at no cost to the patient through the specialist palliative care service.
  • NDIS: May fund palliative-related supports for people aged <65 with a disability co-existing with a life-limiting illness.
  • Home Care Packages (Levels 1โ€“4): Can fund personal care, nursing visits, allied health, and equipment for those already on a package.
  • MBS items for GPs: Chronic Disease Management Plan (Item 721), Team Care Arrangement (Item 723), and GP Mental Health Treatment Plan (Item 710) โ€” all applicable to palliative care patients.

๐Ÿฅ Hospital Care

Hospitals remain the most common place of death in Australia, accounting for approximately half of all deaths. While many hospital-based deaths occur in acute wards, dedicated palliative care consultation services and hospital-based palliative care units provide specialist expertise within the hospital setting.

When Hospital-Based Palliative Care Is Appropriate

Planned Admission
Symptom Investigation or Procedure
Diagnostic workup (e.g. MRI for cord compression), radiation therapy fractions, palliative stenting, paracentesis, or pleural drainage
Setting: General ward with palliative care consultation
Acute Admission
Symptom Crisis
Uncontrolled pain, intractable vomiting, haemorrhage, seizures, acute renal failure, sepsis, or spinal cord compression requiring urgent intervention
Setting: Acute ward, ED; palliative care consult within 24 hours
End-of-Life Admission
Cannot Be Managed at Home
Patient too unwell for transfer, no carer available, acute safety concerns, or patient preference for hospital death with full support
Setting: Palliative care unit, single room with family accommodation

Hospital Palliative Care Consultation Services

Most Australian tertiary and secondary hospitals have specialist palliative care consultation teams (inpatient consultation-liaison). These teams provide:

  • Symptom assessment and management advice to the primary treating team.
  • Goals-of-care discussions and advance care planning documentation.
  • Discharge planning โ€” facilitating timely transition home or to a palliative care unit.
  • Carer support and bereavement risk assessment.
  • Education for ward staff on end-of-life care, syringe driver use, and anticipatory medication prescribing.
โ„น๏ธ
PCOC data: Australian hospitals participating in the Palliative Care Outcomes Collaboration record validated patient-reported outcome measures at admission, key clinical events, and discharge/death. PCOC benchmarks show that specialist palliative care involvement in hospital is associated with improved symptom control (mean reduction in Symptom Assessment Scale scores of โ‰ฅ2 points in 70% of patients within 72 hours) and more frequent documentation of advance care plans.

Emergency Department Palliative Care

Patients with known palliative care needs frequently present to emergency departments, often due to acute symptom crises or carer breakdown. Best-practice ED management includes:

  • Rapid identification of existing advance care directives and goals-of-care documentation (My Health Record, state-based registers, or patient-held documents).
  • Early palliative care consult referral (ideally within 4 hours of presentation) rather than defaulting to full active treatment pathways.
  • Symptom-driven investigations โ€” avoiding non-beneficial interventions (e.g. routine bloods in a patient with documented comfort care goals).
  • Dedicated ED palliative care pathways exist in several Australian hospitals (e.g. Melbourne's Royal Children's Hospital Paediatric Palliative Care ED pathway).

Discharge Planning and Avoiding Unnecessary Readmission

Effective hospital palliative care includes robust discharge planning:

  • Commence anticipatory medications and ensure community pharmacy stock before discharge.
  • Confirm community palliative care team referral and first visit date.
  • Provide written emergency action plan to patient and carer.
  • Ensure equipment delivery arranged (hospital bed, syringe driver if needed).
  • Telephone follow-up within 24โ€“48 hours of discharge by the hospital palliative care team.

๐Ÿก Palliative Care Units

Dedicated palliative care units (PCUs), sometimes called hospices, provide specialist inpatient palliative care for patients with complex needs that cannot be managed in other settings. In Australia, PCUs may be standalone facilities, co-located within hospitals, or operated by non-government organisations (NGOs) such as HammondCare, Sacred Heart Health Service, and various state-based hospice services.

Indications for PCU Admission

  • Refractory symptoms not responding to generalist or community specialist palliative care (e.g. complex pain syndromes, delirium, intractable nausea).
  • Need for specialist procedures: intrathecal drug delivery, nerve blocks, complex syringe driver titration.
  • Carer exhaustion or absence โ€” when the home environment cannot safely support the patient's care needs.
  • Social isolation โ€” patients without family or social support who need 24-hour professional care.
  • Respite admissions โ€” planned short stays (typically 5โ€“14 days) to support carers and prevent burnout.
  • Active dying โ€” when the patient or family prefer a PCU environment over home or hospital for the terminal phase.

PCU Characteristics Compared to Acute Hospital Wards

Feature Palliative Care Unit Acute Hospital Ward
Nurse-to-patient ratio Typically 1:3โ€“4 (day), 1:5โ€“6 (night) 1:6โ€“8 (day), 1:8โ€“12 (night)
Average length of stay 7โ€“14 days (range 1โ€“60+) 3โ€“5 days
Visiting hours Often flexible / 24-hour Restricted (typically 10amโ€“8pm)
Family accommodation Frequently available (sleepover rooms, pull-out beds) Rarely available
Multidisciplinary team Palliative medicine specialist, palliative care nurse, social worker, chaplain, music therapist, volunteer coordinator, OT, physio General medical team ยฑ palliative care consult
Focus of care Quality of life, comfort, family support, bereavement Diagnosis-specific, disease-modifying where appropriate
After-hours medical cover On-site or on-call palliative medicine consultant Hospital RMO / registrar cover

Common Symptom Management in PCUs

PCUs manage complex, refractory symptoms with pharmacological and non-pharmacological approaches. Syringe driver (continuous subcutaneous infusion, CSCI) use is a hallmark of specialist palliative care:

๐Ÿ’‰
Syringe Driver โ€” Common Combinations
CSCI via Graseby MS26 / McKinley T34 ยท Continuous subcutaneous infusion
Pain + agitation Morphine 10โ€“100 mg/24h + midazolam 10โ€“30 mg/24h SC
Pain + nausea + secretions Morphine + haloperidol 2.5โ€“5 mg/24h + hyoscine butylbromide 60โ€“80 mg/24h SC
Agitation alone Midazolam 20โ€“60 mg/24h SC; levomepromazine 25โ€“100 mg/24h SC for refractory cases
Renal impairment Substitute morphine with fentanyl 50โ€“200 mcg/24h or alfentanil 2โ€“8 mg/24h SC
PBS status (syringe drivers) โœ” PBS General Benefit โ€” syringe drivers funded by state programs
๐Ÿšจ
Double-effect doctrine: In Australian palliative care, the principle of double effect is accepted โ€” titrating opioids and sedatives to relieve suffering is ethically and legally permissible even if a foreseeable (but unintended) consequence is respiratory depression and hastening of death. This must be distinguished from euthanasia (Voluntary Assisted Dying legislation varies by state and is governed by separate legislation).

Australian PCU Distribution and Access

As of 2023, Australia has approximately 800โ€“900 dedicated palliative care beds across public hospitals, private hospitals, and NGO-operated hospices. Distribution is heavily weighted to major cities, creating significant access inequity for rural and remote populations. PCOC data indicate median waiting times of 1โ€“3 days for PCU admission in metropolitan areas, extending to 5โ€“14 days or requiring interstate transfer for some regional patients.

  • NSW: HammondCare (Sydney), Sacred Heart (Sydney), Calvary Mater Newcastle, Braeside Hospital, Greenwich Hospital.
  • VIC: Peter MacCallum Cancer Centre, Caritas Christi (St Vincent's), Bethlehem Hospital, Mercy Palliative Care.
  • QLD: Mater Palliative Care, Brisbane South Palliative Care, Gold Coast University Hospital PCU.
  • WA: Bethesda Hospice, SJOG Murdoch, Silver Chain.
  • SA: Mary Potter Hospice (Calvary), Flinders Medical Centre PCU.
  • TAS: Holman Clinic, Hobart.
  • ACT: Clare Holland House (Snowy Monaro region outreach).
  • NT: Darwin palliative care unit (Royal Darwin Hospital).

๐ŸŒพ Rural & Remote Care

Approximately 7 million Australians (28% of the population) live in rural and remote areas defined as MM 3โ€“5 (Modified Monash Model). These communities face persistent barriers to palliative care access including workforce shortages, distance from specialist services, limited after-hours support, and cultural complexities โ€” particularly for Aboriginal and Torres Strait Islander communities.

Modified Monash Model and Palliative Care Access

MM Category Description Palliative Care Access
MM 1โ€“2 (Metropolitan / Regional) Major cities, large regional centres Full access to specialist palliative care, PCUs, consultative teams, community services
MM 3โ€“4 (Rural) Small rural towns (pop. 5,000โ€“15,000) GP-led palliative care with visiting specialist outreach (monthly or quarterly); telehealth support; limited or no PCU access
MM 5โ€“6 (Remote) Remote towns and communities Nurse-led / Aboriginal Health Practitioner-led; Royal Flying Doctor Service (RFDS) support; specialist telehealth; evacuations common for complex symptoms
MM 7 (Very Remote) Very remote Aboriginal communities, islands Significant access barriers; care often requires patient relocation to regional or metropolitan centres; cultural considerations paramount

Strategies for Improving Rural and Remote Palliative Care

1
Specialist Outreach & Telehealth
Scheduled specialist palliative care outreach visits (monthly) with interim telehealth consultations (MBS Items 99200โ€“99215). Queensland's Specialist Palliative Care Rural Telehealth (SPaRTa) model has demonstrated feasibility and high clinician/patient satisfaction.
2
GP & Rural Generalist Upskilling
Training rural GPs and rural generalists in palliative care through programs such as the Australian and New Zealand Society of Palliative Medicine (ANZSPM) certificate courses, Palliative Care Australia online modules, and RACGP Certificate of Advanced Training in Palliative Care.
3
Community Nurse & Aboriginal Health Practitioner Training
Equipping remote area nurses (RANs) and Aboriginal Health Practitioners (AHPs) with palliative care competencies including symptom assessment (POS-S), syringe driver management, end-of-life care, and cultural liaison roles.
4
Emergency Transfer Protocols
Clear protocols for aeromedical retrieval via RFDS or state services when symptoms are refractory and local management is unsafe. Advance documentation of transfer preferences (including refusal of transfer) is essential.
5
Medication & Equipment Logistics
Pre-positioning essential palliative medications and equipment in remote clinics. Utilising Section 100 (Remote Area Aboriginal Health Services) supply arrangements for opioid access. Ensuring cold-chain compliance for injectable medications in tropical climates.
โš ๏ธ
Equity concern: The Australian Charter of Healthcare Rights mandates equitable access to palliative care regardless of location. Evidence shows rural Australians are 2โ€“3 times more likely to die in hospital rather than their preferred setting, and have lower rates of specialist palliative care involvement (AIHW Palliative Care Services in Australia 2023). Systemic investment in rural palliative care workforce, infrastructure, and telehealth is required to close this gap.

Key Rural & Remote Palliative Care Services

  • Royal Flying Doctor Service (RFDS): Aeromedical retrieval and remote consultations, including palliative care support, across all states and territories.
  • CareSearch / palliAGED: National online evidence-based resources for palliative care in aged care and rural settings.
  • Program of Experience in the Palliative Approach (PEPA): Funded by the Australian Government, PEPA provides clinical placements for health professionals to build palliative care skills in generalist settings.
  • End-of-Life Directions for Aged Care (ELDAC): Online toolkit and advisory service for aged care providers, including RACFs in rural areas.

๐Ÿ‘ฅ Special Populations

๐Ÿคฐ

Pregnancy

Palliative care in pregnancy is rare but critical when advanced cancer or other life-limiting illness is diagnosed during gestation.

Opioids: Morphine and oxycodone cross the placenta; use lowest effective dose. Neonatal withdrawal may occur with chronic use in the third trimester.

Midazolam: Avoid in first trimester (Category D); use with caution in late pregnancy โ€” neonatal respiratory depression possible.

Setting: Tertiary hospital with obstetric and neonatal services is preferred. Home-based palliative care may be considered in late pregnancy with multidisciplinary planning.

๐Ÿ‘ถ

Paediatrics

Approximately 800 children die from life-limiting conditions in Australia annually. Most paediatric palliative care is delivered at home, with specialist support from children's hospital teams.

Paediatric palliative care teams: Available at all children's hospitals nationally (e.g. Bear Cottage โ€” Sydney, Very Special Kids โ€” Melbourne, Hummingbird House โ€” Brisbane).

Medication: Weight-based dosing essential. Syringe drivers (e.g. CADD-MS 3) with small-volume reservoirs suitable for paediatric use.

Bereavement: Sibling support and school liaison are integral components of paediatric palliative care. Bear Cottage and Very Special Kids provide ongoing family bereavement programs.

๐Ÿ‘ด

Elderly

Over 70% of deaths in Australia occur in people aged โ‰ฅ65 years. RACFs are the second most common place of death.

Opioid caution: Start at 50% of standard adult dose; increased sensitivity, reduced clearance, falls risk. Hydromorphone preferred over morphine if eGFR <30 mL/min.

Delirium: Common at end of life; haloperidol 0.5โ€“1 mg PO/SC (low-dose), risperidone 0.25โ€“0.5 mg as alternatives. Avoid benzodiazepines as first-line in delirium unless related to alcohol withdrawal.

ELDAC toolkit: Free online resource for RACF staff (eldac.com.au) with care planning templates, medication guides, and advance care planning tools.

๐Ÿซ˜

Renal Impairment

CKD stages 4โ€“5 and dialysis-dependent patients have complex symptom burdens. Withdrawal from dialysis is an increasingly common pathway to palliative care (approximately 15% of dialysis deaths in Australia).

Avoid: Morphine (active metabolite M6G accumulates); NSAIDs. Prefer fentanyl, alfentanil, or hydromorphone.

Gabapentin: Requires significant renal dose reduction (100 mg after each dialysis session for neuropathic pain).

Setting: Home or RACF if stable; inpatient PCU if dialysis withdrawal is planned, to manage symptoms of uraemia (pruritus, nausea, restlessness) over 7โ€“14 days.

๐Ÿซ

Hepatic Impairment

End-stage liver disease (ESLD) has a symptom burden comparable to advanced cancer, including ascites, encephalopathy, pruritus, and muscle cramps.

Opioids: Reduce dose by 50%; prefer fentanyl (hepatically metabolised but less affected by synthetic capacity). Avoid codeine and tramadol.

Midazolam: Prolonged half-life in cirrhosis; reduce dose by 50% and titrate cautiously.

Setting: Community care if Child-Pugh A/B; inpatient for Child-Pugh C with encephalopathy or haemodynamic instability.

๐Ÿ›ก๏ธ

Immunocompromised

Patients with HIV/AIDS (despite effective ART), organ transplant recipients, and those on immunosuppressive therapy may develop life-limiting complications requiring palliative care.

HIV: Palliative care involvement should begin early in advanced HIV; symptom management includes antiretroviral continuation where tolerated, treatment of opportunistic infections, and psychosocial support.

Infection risk: Home palliative care may need infection control precautions for neutropenic patients; discuss with infectious disease and palliative care teams.

Aboriginal and Torres Strait Islander Health Considerations
Cultural understanding of death
Aboriginal and Torres Strait Islander peoples have diverse cultural practices around death and dying, including Sorry Business โ€” a period of mourning with specific obligations regarding naming of the deceased, avoidance practices, and community gatherings. These practices vary significantly between communities and must be respected without generalisation. Naming restrictions may mean that a deceased person's name (or similar-sounding names) is avoided, which has implications for documentation and communication.
Returning to Country
Many Aboriginal and Torres Strait Islander people express a strong preference to return to their Country for end-of-life care and death. This may involve complex logistics including aeromedical or road transport, coordination with remote health clinics, and ensuring family can gather. Health services should facilitate this where safely possible and begin planning early.
Aboriginal Community Controlled Health Organisations (ACCHOs)
ACCHOs such as the Aboriginal Medical Services Alliance of the Northern Territory (AMSANT), VACCHO (Victoria), and QAIHC (Queensland) play a critical role in culturally safe palliative care delivery. Integration between ACCHOs and mainstream palliative care services improves trust, access, and outcomes. Over 140 ACCHOs operate nationally, providing primary care that can incorporate palliative care principles.
Workforce and access barriers
Aboriginal and Torres Strait Islander peoples have lower access to specialist palliative care services compared to non-Indigenous Australians (0.4 vs 1.2 episodes per 1,000 population). Key barriers include: cultural unsafety of mainstream services, lack of Aboriginal Health Workers in palliative care, distrust of institutional care, distance from services, and communication barriers. Training Aboriginal Health Workers and Practitioners in palliative care (e.g. through PEPA placements) is a national priority.
Family-centred and community models
Palliative care for Aboriginal and Torres Strait Islander peoples should adopt family-centred and community-driven models. This means engaging extended family in care planning, using interpreters where English is not the first language (recognising that many Aboriginal people speak English as a second, third, or fourth language), and involving Elders and community leaders in goals-of-care discussions. Written materials should be available in local languages where possible.
Available resources
Palliative Care Australia โ€” Aboriginal and Torres Strait Islander Palliative Care resources: Practice guides for culturally safe care. Carers Australia: Support for Indigenous carers. RACGP โ€” Specific Interests: Aboriginal and Torres Strait Islander Health: GP education modules. AIHW โ€” Palliative care services in Australia: National data on Indigenous palliative care access.

๐Ÿ“š References

  1. 1. Australian Government Department of Health. National Palliative Care Strategy 2018. Canberra: Commonwealth of Australia; 2018.
  2. 2. Australian Institute of Health and Welfare. Palliative care services in Australia. AIHW; 2023. Cat. no. HWV 84.
  3. 3. Palliative Care Outcomes Collaboration (PCOC). National Bulletin โ€” 2023 results. Wollongong: University of Wollongong; 2024.
  4. 4. Swerissen H, Duckett S. What can we do to help Australians die the way they want? Grattan Institute Report No. 2014-8. Melbourne: Grattan Institute; 2014.
  5. 5. Palliative Care Australia. National Palliative Care Standards. 5th ed. Canberra: PCA; 2018.
  6. 6. Australian and New Zealand Society of Palliative Medicine (ANZSPM). Specialist palliative medicine physician training curriculum. ANZSPM; 2022.
  7. 7. Department of Health and Aged Care. Modified Monash Model โ€” Fact sheet. Canberra: Australian Government; 2019. Available at: www.health.gov.au.
  8. 8. Mitchell GK, Senior HE, Bibo MP, et al. Palliative care in rural and remote Australia: challenges and solutions. Aust J Rural Health. 2020;28(2):116โ€“124.
  9. 9. CareSearch / palliAGED. Palliative care evidence and resources for aged care. Adelaide: Flinders University; 2024. Available at: caresearch.com.au.
  10. 10. Royal Australian College of General Practitioners (RACGP). Palliative care in general practice โ€” RACGP curriculum. Melbourne: RACGP; 2023.
  11. 11. World Health Organization. Palliative care โ€” Key facts. Geneva: WHO; 2020. Available at: www.who.int.
  12. 12. Australian Government Department of Health. End-of-Life Directions for Aged Care (ELDAC) project. Canberra: Commonwealth of Australia; 2023. Available at: eldac.com.au.
  13. 13. McGrath PD, Rawson-Huff N, Holewa H. Programs of experience in the palliative approach (PEPA) โ€” strengthening the palliative care workforce. Aust Health Rev. 2019;43(4):437โ€“441.
  14. 14. Croager EJ, Gray C, Eades S, et al. Aboriginal and Torres Strait Islander palliative care: a review of the literature. Aust J Prim Health. 2021;27(5):353โ€“361.
  15. 15. National Aboriginal Community Controlled Health Organisation (NACCHO). Providing culturally safe palliative care for Aboriginal and Torres Strait Islander peoples โ€” Position paper. Canberra: NACCHO; 2022.
for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.
Preventive health
Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction
Paracetamol ยฑ NSAID; manual therapy
2โ€“6 weeks
Provocable on palpation; no red flags
Thoracic compression fracture
Paracetamol; ยฑ calcitonin; DXA + osteoporosis Rx
6โ€“12 weeks healing
Elderly; osteoporosis; acute onset
ACS (posterior MI)
Aspirin 300 mg, GTN, heparin; urgent PCI
Time-critical
ECG, troponin; CV risk factors
Aortic dissection
IV labetalol; urgent CT aortogram; surgery (Type A)
Time-critical
Tearing pain; BP differential >20 mmHg
Vertebral osteomyelitis
IV antibiotics (vancomycin + ceftriaxone initially); ID consult
6 weeks IV antibiotics
Fever, elevated CRP, IV drug use
Biliary colic / cholecystitis
Paracetamol ยฑ morphine; lap cholecystectomy
Surgical within 72 h (cholecystitis)
RUQ/infrascapular; post-prandial; RUQ US

๐Ÿ“š References

  1. 1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
  2. 2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
  3. 3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
  4. 4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760โ€“765.
  5. 5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60โ€“75.
  6. 6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395โ€“403.
  7. 7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  8. 8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581โ€“E593.
  9. 9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112โ€“120.
  10. 10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144โ€“153.
  11. 11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
  12. 12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805โ€“811.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3โ€“4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

๐Ÿ“š References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924โ€“939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736โ€“745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583โ€“1599.
  5. 5. Smolen JS, Landewรฉ RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3โ€“18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487โ€“1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing โ€” misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Associationโ€“European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771โ€“1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFฮฑ blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155โ€“158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3โ€“4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

๐Ÿ“š References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924โ€“939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736โ€“745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583โ€“1599.
  5. 5. Smolen JS, Landewรฉ RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3โ€“18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487โ€“1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing โ€” misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Associationโ€“European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771โ€“1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFฮฑ blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155โ€“158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).